Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease
This systematic review and meta-analysis investigates the associated risk of inflammatory bowel disease in patients with hidradenitis suppurativa.
Introduction: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) are both chronic inflammatory diseases with a big impact in the quality of life of the patients. It has been described a higher prevalence of HS among patients diagnosed with IBD, especially Crohn disease. Some drugs used in HS, such as antibiotics, can be harmful for IBD patients and they may trigger flare ups. Adalimumab is anti-TNF drug which is approved for the treatment of both diseases, being the doses similar in both disorders.
We present a 24 year old female with a 4 year history of hidradenitis suppurativa (HS) and nodulocystic acne who developed vitiligo 4 mon ths after commencing adalimumab. Anti TNF therapy has been successfully used in other diseases, where the development of vitiligo has been noted in case reports.
CONCLUSION: Guselkumab represents a promising therapeutic option for recalcitrant HS patients with inflammatory comorbidities in which IL-23 plays a role. PMID: 31389737 [PubMed - as supplied by publisher]
This article is protected by copyright. All rights reserved. PMID: 31396947 [PubMed - as supplied by publisher]
ConclusionsThis study demonstrates that the risk of developing a second IMID is significantly higher for individuals who have already experienced a first IMID in a large and contemporary US claims database. Certain pairs of IMIDs co-occur more frequently than others. The risk of developing subsequent IMIDs may be an important consideration for clinicians when selecting treatment strategies.FundingAbbvie.
Conclusions In this review, we collected all the information concerning the OMICs studies performed on HS patients aimed at unraveling the mechanisms at the basis of the disease or associated to clinical severity and/or the successful response to pharmacological treatment (including biological drugs). The general picture of the OMICs contribution in the context of HS is not so clear and/or rich of clinical useful information, since most of the studies focused only on one aspect (genome, transcriptome, or proteome) of the disease, enrolling small numbers of patients (this is quite limiting for the genetic studies) from di...
ConclusionsThis study suggests that approximately 67% of male AS patients and 77% of female AS patients newly initiating a TNFi do not remain on the index therapy 2 year post initiation.FundingEli Lilly and Company.
To the Editor: Hidradenitis suppurativa (HS) is associated with several comorbidities, including possibly spondyloarthritis.1 Spondyloarthritis is a group of interrelated chronic autoinflammatory rheumatic conditions.2 A spondyloarthritis diagnosis is based mainly on the presence of spondyloarthritis features, which includes spinal (axial) features sacroiliitis and spondylitis, peripheral features, such as peripheral arthritis, enthesitis, and dactylitis; and the extra-articular manifestations uveitis, psoriasis, and inflammatory bowel disease.
Authors: Pescitelli L, Ricceri F, Prignano F Abstract Hidradenitis suppurativa is a chronic, inflammatory, recurrent, debilitating skin disease characterized by recurrent abscesses, draining sinuses, and scarring, affecting principally areas of body friction. Although the disease pathogenesis is not fully understood, recent advances suggest that hidradenitis suppurativa should be viewed as a systemic inflammatory disease. Moreover, recent studies have defined hidradenitis suppurativa as a systemic disease linked to several comorbidities. Metabolic disorders including obesity and metabolic syndrome are the most comm...
CONCLUSIONS: HS is associated with a variety of comorbid conditions that should be considered to perform targeted routine screening and to improve HS management. PMID: 30295448 [PubMed - as supplied by publisher]